Aroa Biosurgery Ltd.

HACKENSACK, N.J., Jan. 15, 2026 /PRNewswire/ -- Royal Biologics, a leader in innovative biologic solutions for wound care and tissue repair, today announced it has signed an exclusive distribution agreement with Aroa Biosurgery for Myriad Matrix™ Restore, expanding access to advanced soft tissue repair solutions across outpatient and mobile care settings in the United States. Under the terms of the agreement, Royal Biologics will serve as the exclusive outpatient distributor of Myriad Matrix™ Restore, bringing this cutting-edge regenerative product to a broad patient population outside of the hospital setting. Establishing this partnership reinforces Royal Biologics' commitment to delivering high-impact biologic solutions that improve patient outcomes and enhance care delivery. Royal Biologics CEO Salvatore Leo stated, "We are excited to announce our exclusive strategic distribution partnership with AROA. Backed by years of credible clinical evidence and global success, the Myriad ™ brand represents a meaningful advancement in wound care. We are proud to bring Myriad Matrix™ Restore to clinicians and providers in 2026, offering a differentiated, innovative solution at a time when the wound care market is undergoing significant change and seeking new alternatives to traditional options. Launching in 2026, Myriad Matrix™ Restore offers clinicians a compelling alternative in a market where there has been limited recent innovation." About Myriad Matrix™ Restore Myriad Matrix™ Restore is an engineered extracellular matrix bioscaffold designed to support soft tissue repair, reinforcement, and complex wound healing. It is constructed from layers of AROA ECM™, a biologic scaffold derived from ovine forestomach tissue that retains a rich array of structural and signaling proteins essential to natural tissue healing. Myriad Matrix™ Restore is engineered with perforations and interstitial spaces that facilitate rapid cell infiltration and angioconduction, helping to accelerate the body's regenerative response and promote organized tissue formation. 1 The product is strong and adaptable, easy to trim and handle, and indicated across a range of wound types, including partial- and full-thickness wounds, pressure ulcers, diabetic and venous ulcers, surgical and traumatic wounds, and more. 1 About Royal Biologics Royal Biologics is dedicated to advancing wound care and soft tissue repair through a curated portfolio of biologic and regenerative products. With a focus on clinician support, patient outcomes, and broad access across sites of service, Royal Biologics partners with healthcare providers to deliver innovative and reliable solutions that drive healing where it matters most. References Aroa Biosurgery. Myriad Matrix™ Extracellular Matrix (ECM). Available at: For further information: Media contact: Mary Jo Murino [email protected] SOURCE Royal Biologics 21% more press release views with Request a Demo

AUCKLAND, New Zealand, Aug. 27, 2025 /PRNewswire/ -- AROA is pleased to announce the findings of the first in human study involving its new ENIVO platform technology. The study is the subject of a peer-reviewed publication entitled Prospective, First-in-Human Clinical Evaluation of a Novel Tissue Apposition Device (ENIVO™) Following Simple Unilateral Mastectomy, which was published in the well-respected journal, Plastic and Reconstructive Surgery, Global Open. The ENIVO platform is designed for the management of 'dead space,' which is an open cavity created by surgical separation or excision of soft tissue. Dead spaces commonly fill with seroma, which can lead to secondary complications, increase the risk of infection, and lengthen hospital stays for patients. AROA's novel ENIVO system is comprised of a wearable vacuum pump connected to a tube and an Aroa ECM sleeve which is implanted within the patient's body. It delivers suction to the surgical site and allows the tissue surfaces at the surgical site to be held closely together, aiming to eliminate the dead space, remove fluid, and improve the speed and quality of healing. The multi-center study, which involved ten patients who had undergone simple unilateral mastectomy where all tissue from one breast is removed, was conducted in New Zealand and led by Associate Professor Michelle B. Locke, MBChB MD. The ENIVO system was used as an alternative to a surgical drain, which is the current standard of care. The shortcomings of drains are well-known - they can fail due to blockages and often lead to seroma formation. Seromas (a collection of fluid that accumulates in a surgical cavity) are one of the most common complications following mastectomy, with reported incidence rates as high as 22-43%.[1] Seromas are associated with delayed wound healing, increased risk of infection and unsatisfactory aesthetic results. The study monitored the patients for a period of three months postoperatively and found that the ENIVO device performed as designed and all patients healed well, with only one clinically relevant seroma recorded. AROA CEO Brian Ward says: "We're pleased to see this first ENIVO clinical study published. The results are promising, and it's pleasing to see the device has functioned exceptionally well in a procedure where complications have serious consequences for the patient's care. While further research is required, the findings of this first study support our belief that ENIVO could pave the way for a new standard of care in a wide range of surgeries where managing dead space is challenging. ENIVO has the potential to significantly reduce complications, positively impact patient outcomes, and reduce treatment costs". Associate Professor Locke says: "It was rewarding to collaborate with AROA and the New Zealand based surgical teams to lead this first human study of the ENIVO system. The device functioned well, the study results were encouraging, and I am optimistic that this innovation could significantly improve patient outcomes following surgery." AROA estimates the market opportunity for ENIVO to be in excess of US$1B[2], and is actively pursuing commercialisation, with two out of three of the components already having received US FDA clearance. The study is available online, here *ENIVO is a device in development and is not currently cleared for use in the tested configuration within the United States. Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO. About Aroa Biosurgery: Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine forestomach. AROA has commercialised four product families based on its AROA ECM technology, targeting chronic wounds, hernia, soft tissue, and breast reconstruction. Over 7 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. AROA has regulatory approvals in more than 50 countries. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). SOURCE Aroa Biosurgery WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AUCKLAND, New Zealand, May 1, 2025 /PRNewswire/ -- Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence. There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology. Continue Reading AROA's most recent publication was a large retrospective analysis of real-world evidence (RWE) from wound care centers in the US, assessing the efficacy of the company's Endoform NaturalTM product in treating venous leg ulcers (VLUs), in comparison to a leading reconstituted collagen dressing. VLU's are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful. These types of wounds are difficult for clinicians to treat successfully. For example, only ~40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur[1]. The peer-reviewed study, entitled "Clinical Efficacy of Ovine Forestomach Matrix and Collagen/Oxidized Regenerated Cellulose for the Treatment of Venous Leg Ulcers: A Retrospective Comparative Real-World Evidence Study" was published in the open access journal 'International Wound Journal in April 2025. The study compared 470 VLU's that had been treated with Endoform Natural to 360 VLU's that had been treated with a reconstituted collagen product. The study used existing data from 223 wound care centers with minimal inclusion or exclusion criteria so that 'real-world' use of both products could be compared. "There is a growing awareness of RWE studies to validate clinical performance" says Chief Scientific Officer, Dr. Barnaby May. "These types of studies enable much larger patient numbers to be compared versus traditional randomized controlled trials. Given that RWE studies use data from 'real-world' use of a treatment, the results can be more meaningful, especially in wound care where there is a high degree of variability in how wounds are cared for and patient factors." The study found that VLUs treated with Endoform Natural healed up to ~ 8 weeks faster versus the comparator group, and the chances of the wound healing were significantly improved when Endoform Natural was used as part of treatment. The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs were treated using Endoform Natural. Dr. Gregory Bohn MD was part of the research team. "I was first introduced to Endoform in 2012 and started using the product to treat my own patients with VLUs. This new data validates what I have seen in my own practice managing VLUs with Endoform." This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituted collagen dressing. A previous study included the analysis of over 2,200 diabetic foot ulcers (DFUs) and also demonstrated significantly faster healing of DFUs using Endoform Natural[2]. The study is available online here. SOURCE Aroa Biosurgery WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED